Toggle Main Menu Toggle Search

Open Access padlockePrints

Effect of cell cycle inhibition on cisplatin-induced cytotoxicity

Lookup NU author(s): Professor Herbie Newell, Professor Roger Griffin, Richard Davison, Lan Wang, Professor Nicola CurtinORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Pharmacological inhibitors of cyclin-dependent kinase (CDK)2 are currently in preclinical and clinical development. The purpose of our work was to evaluate a series of guanine derivatives for their ability to inhibit CDK2, affect cell cycle progression, and enhance the cytotoxic and apoptotic effects of cisplatin. A panel of guanine derivatives, including O6-benzylguanine (O 6-BG), S6-benzyl-6-thioguanine (S6-BG), S 6-[(cyclohexyl)methyl]-6-thioguanine (S6-CMG), O 6-[(cyclohexyl)methyl]guanine (O6-CMG), O 6-benzyl-9-methylguanine (9-CH3-BG), O6- [(cyclohexyl)methyl]-9-methylguanine (9-CH3-CMG), and 7-benzylguanine (N7-BG), exhibited varying degrees of CDK2 inhibition with O6-CMG being the most potent and 9-CH3-BG, 9-CH3-CMG, and N7-BG the least potent compounds. Treatment with S6-CMG and O 6-CMG significantly decreased the percentage of cells in S phase. In SQ20b and SCC61 head and neck cancer cell lines, the most potent CDK2 inhibitor, O6-CMG, was also the most effective at enhancing cisplatin-induced cytotoxicity and apoptosis. Cisplatin-induced DNA platination increased in SQ20b cells pretreated with S6-BG, S6-CMG, and O 6-CMG. Treatment with both O6-BG and trichostatin A, an indirect cell cycle inhibitor, demonstrated additive effects on cisplatin-induced cytotoxicity. In summary, we have identified a group of guanine derivatives that were effective modulators of cisplatin-induced cytotoxicity and apoptosis.

Publication metadata

Author(s): Fishel M, Newell D, Griffin R, Davison R, Wang L, Curtin NJ, Zuhowski E, Kasza K, Egorin M, Moschel R, Dolan M

Publication type: Article

Publication status: Published

Journal: Journal of Pharmacology and Experimental Therapeutics

Year: 2005

Volume: 312

Issue: 1

Pages: 206-213

Print publication date: 01/01/2005

ISSN (print): 0022-3565

ISSN (electronic): 1521-0103


DOI: 10.1124/jpet.104.073924

PubMed id: 15304523


Altmetrics provided by Altmetric


Funder referenceFunder name